Observational studyBMC nephrology2026
A retrospective multicenter cohort study of patients with sarcoidosis and renal involvement.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is a multisystem granulomatous disease that can involve the kidneys. Renal involvement is often asymptomatic and underdiagnosed, yet timely recognition and treatment are crucial to prevent irreversible kidney damage. Despite its importance, there is a lack of established treatment guidelines for renal sarcoidosis.
methodsWe conducted a retrospective multicenter study across six Dutch hospitals, including patients with biopsy-proven renal sarcoidosis diagnosed between 2010 and 2024. Clinical, laboratory, histopathological, treatment, and outcome data were collected from electronic medical records. Descriptive statistics were used to summarize findings.
resultsTwenty-nine patients with biopsy-proven renal sarcoidosis were included (median age 56 years; 66% male). Lung involvement was present in 48%, and hypercalcemia in 45% of patients. At diagnosis, median serum creatinine was 242 µmol/L and median eGFR was 23 mL/min/1.73 m². Granulomatous inflammation was present in 76% of biopsies. All patients received corticosteroids as first-line therapy (median initial prednisone dose 0.66 mg/kg/day). Maximal improvement in kidney function was observed within one month of treatment; no significant predictors for early response were identified. Relapses occurred in 48% of patients (median time to first relapse: 7 months), often during or after tapering of corticosteroids. Additional immunosuppressive agents were used in 45% of patients, mainly after relapse. No baseline factors predicted relapse risk.
conclusionsThis study confirms the heterogeneous presentation of sarcoidosis and underscores the need for better biomarkers to guide treatment and decision making in these patients. Early corticosteroid therapy leads to rapid improvement in kidney function, but relapse is common during tapering. Steroid-sparing agents are effective for relapsing disease. Close monitoring during and after corticosteroid tapering is warranted. Our findings support a treatment protocol starting with prednisone 0.5–1 mg/kg/day, followed by gradual tapering, and the addition of steroid-sparing agents in case of relapse. Further prospective studies are needed to optimize treatment strategies and identify predictive markers for relapse and response. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.